STAT Plus: Otsuka Pharma signs $430m deal to buy Visterra and its antibody therapies

The Japanese drug maker Otsuka Pharmaceutical has signed a deal to buy Waltham, Mass.-based Visterra for $430 million, the latest example of a foreign pharmaceutical company establishing a presence in the white-hot Massachusetts biotech cluster.

The boards of both companies announced Wednesday that they had approved the all-cash transaction, which is expected to close in the third quarter of this year.